Comparison tool

Dulaglutide vs CagriSema side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

DulaglutideCagriSema

Share this peptide comparison

Property	Dulaglutide	CagriSema
Category	Weight Loss	Weight Loss
Also known as	Trulicity	Semaglutide + Cagrilintide
FDA approved	Yes	No
Clinical status	FDA Approved - Type 2 diabetes Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	NDA submitted Dec 18, 2025; FDA decision expected Q4 2026. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Blood sugar control, weight management, diabetes	Maximum weight loss, combination therapy, obesity
How it works	Dulaglutide is presented as a GLP-1 receptor agonist. The supplied mechanism states that GLP-1 receptor activation supports insulin release when glucose is present, reduces glucagon, and slows gastric emptying. The molecule is described as a modified GLP-1 peptide attached to a human antibody Fc fragment; the source says this larger Fc-linked design reduces rapid renal clearance and helps protect the peptide from DPP-4 degradation. Appetite and modest weight-related effects are attributed in the source to GLP-1 signaling in hunger-regulating brain regions.	CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analog. The source links semaglutide to insulin response after meals, delayed gastric emptying and fullness signaling, while cagrilintide is described as acting through amylin-related satiety pathways in the brain. The proposed research rationale is that concurrent GLP-1 and amylin signaling may produce stronger appetite effects than either pathway alone.
Typical dosing	1.5-4.5 mg weekly · Once weekly	Limited community data available · See research protocols
Research dosing	0.75mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly	Semaglutide 2.4 mg + cagrilintide 2.4 mg weekly · Weekly · Long-term use expected · Subcutaneous injection weekly
Typical duration	Long-term / chronic use	Long-term use expected
Administration	Subcutaneous injection weekly	Subcutaneous injection weekly
Timing	Before bed or morning (fasted) Take on empty stomach	-
Evidence level	FDA Approved	Clinical Trials
Possible side effects	Nausea (Listed by source; gastrointestinal effects are described as typical downsides.) Diarrhea (Listed by source; gastrointestinal effects are described as typical downsides.) Vomiting (Listed by source.) +7 more Abdominal pain (Listed by source.) Injection site reactions (Listed by source.) Hypoglycemia (with insulin/sulfonylureas) (Source qualifies this risk as occurring with insulin or sulfonylureas.) Pancreatitis (Listed by source.) Gallbladder problems (Listed by source.) BOXED WARNING: Thyroid C-cell tumors (Source states this boxed warning is based on rodent data.) FDA approved (Trulicity) (Listed in the source side-effects array, but this is a regulatory/identity note rather than an adverse effect.)	Nausea (Reported as a gastrointestinal adverse effect in the source.) Vomiting (Reported as a gastrointestinal adverse effect in the source.) Diarrhea (Reported as a gastrointestinal adverse effect in the source.) +4 more Constipation (Reported as a gastrointestinal adverse effect in the source.) Gastrointestinal events (The source reports 72-80% with CagriSema compared with 34-40% for placebo.) Higher gastrointestinal effects than semaglutide alone (Listed in the source side-effect field.) Investigational status (The source notes that CagriSema is not yet approved.)
Research summary	The source characterizes Dulaglutide as supported by human clinical evidence rather than only animal work. It cites the AWARD program for glucose-lowering evidence across multiple type 2 diabetes contexts. It also highlights the 2019 Lancet REWIND trial, which followed more than 9,900 participants for a median period exceeding five years; about 69% reportedly had no previous cardiovascular disease. In that trial summary, major cardiovascular events were lower with dulaglutide than placebo, reported as 12.0% versus 13.4% with a hazard ratio of 0.88. The source notes gastrointestinal tolerability issues such as nausea and diarrhea and states that the class carries a boxed warning about thyroid C-cell tumors based on rodent findings.	The supplied research summary describes two phase 3 REDEFINE studies. In REDEFINE 1, about 3,400 adults with overweight or obesity without diabetes were followed for 68 weeks; reported average body-weight change was about 20.4% with CagriSema, compared with 14.9% for semaglutide, 11.5% for cagrilintide and 3.0% for placebo. REDEFINE 2 enrolled adults with type 2 diabetes and is described as meeting endpoints for weight reduction and HbA1c improvement versus placebo. The source also notes that the approximately 20% result was below Novo Nordisk's 25% target, and that gastrointestinal events were the most common adverse effects.
References	Source Source +1 more Source	New England Journal of Medicine New England Journal of Medicine +2 more American Diabetes Association Novo Nordisk
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Dulaglutide

CagriSema

Category

Weight Loss

Also known as

Trulicity

Semaglutide + Cagrilintide

FDA approved

Yes

Clinical status

FDA Approved - Type 2 diabetes

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

NDA submitted Dec 18, 2025; FDA decision expected Q4 2026.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Blood sugar control, weight management, diabetes

Maximum weight loss, combination therapy, obesity

How it works

Dulaglutide is presented as a GLP-1 receptor agonist. The supplied mechanism states that GLP-1 receptor activation supports insulin release when glucose is present, reduces glucagon, and slows gastric emptying. The molecule is described as a modified GLP-1 peptide attached to a human antibody Fc fragment; the source says this larger Fc-linked design reduces rapid renal clearance and helps protect the peptide from DPP-4 degradation. Appetite and modest weight-related effects are attributed in the source to GLP-1 signaling in hunger-regulating brain regions.

CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analog. The source links semaglutide to insulin response after meals, delayed gastric emptying and fullness signaling, while cagrilintide is described as acting through amylin-related satiety pathways in the brain. The proposed research rationale is that concurrent GLP-1 and amylin signaling may produce stronger appetite effects than either pathway alone.

Typical dosing

1.5-4.5 mg weekly · Once weekly

Limited community data available · See research protocols

Research dosing

0.75mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly

Semaglutide 2.4 mg + cagrilintide 2.4 mg weekly · Weekly · Long-term use expected · Subcutaneous injection weekly

Typical duration

Long-term / chronic use

Long-term use expected

Administration

Subcutaneous injection weekly

Timing

Before bed or morning (fasted)

Take on empty stomach

Evidence level

FDA Approved

Clinical Trials

Possible side effects

Nausea (Listed by source; gastrointestinal effects are described as typical downsides.)
Diarrhea (Listed by source; gastrointestinal effects are described as typical downsides.)
Vomiting (Listed by source.)

+7 more

Abdominal pain (Listed by source.)
Injection site reactions (Listed by source.)
Hypoglycemia (with insulin/sulfonylureas) (Source qualifies this risk as occurring with insulin or sulfonylureas.)
Pancreatitis (Listed by source.)
Gallbladder problems (Listed by source.)
BOXED WARNING: Thyroid C-cell tumors (Source states this boxed warning is based on rodent data.)
FDA approved (Trulicity) (Listed in the source side-effects array, but this is a regulatory/identity note rather than an adverse effect.)

Nausea (Reported as a gastrointestinal adverse effect in the source.)
Vomiting (Reported as a gastrointestinal adverse effect in the source.)
Diarrhea (Reported as a gastrointestinal adverse effect in the source.)

+4 more

Constipation (Reported as a gastrointestinal adverse effect in the source.)
Gastrointestinal events (The source reports 72-80% with CagriSema compared with 34-40% for placebo.)
Higher gastrointestinal effects than semaglutide alone (Listed in the source side-effect field.)
Investigational status (The source notes that CagriSema is not yet approved.)

Research summary

The source characterizes Dulaglutide as supported by human clinical evidence rather than only animal work. It cites the AWARD program for glucose-lowering evidence across multiple type 2 diabetes contexts. It also highlights the 2019 Lancet REWIND trial, which followed more than 9,900 participants for a median period exceeding five years; about 69% reportedly had no previous cardiovascular disease. In that trial summary, major cardiovascular events were lower with dulaglutide than placebo, reported as 12.0% versus 13.4% with a hazard ratio of 0.88. The source notes gastrointestinal tolerability issues such as nausea and diarrhea and states that the class carries a boxed warning about thyroid C-cell tumors based on rodent findings.

The supplied research summary describes two phase 3 REDEFINE studies. In REDEFINE 1, about 3,400 adults with overweight or obesity without diabetes were followed for 68 weeks; reported average body-weight change was about 20.4% with CagriSema, compared with 14.9% for semaglutide, 11.5% for cagrilintide and 3.0% for placebo. REDEFINE 2 enrolled adults with type 2 diabetes and is described as meeting endpoints for weight reduction and HbA1c improvement versus placebo. The source also notes that the approximately 20% result was below Novo Nordisk's 25% target, and that gastrointestinal events were the most common adverse effects.

References

Source Source

+1 more

Source

New England Journal of Medicine New England Journal of Medicine

+2 more

American Diabetes Association Novo Nordisk

Full profile

View Details